REG - Advanced Oncotherapy - Total Voting Rights

Advanced OncotherapyAnnouncement

29/04/2022 17:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220429:nRSc9262Ja&default-theme=true

RNS Number : 9262J  Advanced Oncotherapy PLC  29 April 2022

29 April 2022

 

ADVANCED ONCOTHERAPY PLC

 

("Advanced Oncotherapy" or the "Company")

 

Total Voting Rights

 

Advanced Oncotherapy (AIM: AVO), the developer of LIGHT, the next-generation
proton therapy system for cancer treatment, announces that the Company's
issued share capital as at the date of this announcement comprises 466,612,211
ordinary shares of 25p each, with one voting right per share ("Ordinary
Shares"). The Company does not hold any Ordinary Shares in treasury and
therefore the total number of Ordinary Shares with voting rights in the
Company is 466,612,211. This announcement is required to be made at month
end in accordance with the FCA's Disclosure Guidance and Transparency Rules.

 

The above figure of 466,612,211 may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the share capital
of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 Advanced Oncotherapy plc                                    www.avoplc.com (http://www.avoplc.com/)
 Dr Michael Sinclair, Executive Chairman                     Tel: +44 (0) 20 3617 8728
 Nicolas Serandour, CEO

 Allenby Capital Limited (Nomad and Joint Broker)
 Nick Athanas / Liz Kirchner (Corporate Finance)             Tel: +44 (0) 20 3328 5656

 Amrit Nahal / Matt Butlin (Sales & Corporate Broking)

 SI Capital Ltd (Joint Broker)
 Nick Emerson                                                Tel: +44 (0) 1483 413 500
 Jon Levinson                                                Tel: +44 (0) 20 3871 4066

 FTI Consulting (Financial PR & IR)                          advancedoncotherapy@fticonsulting.com
                                                             (mailto:advancedoncotherapy@fticonsulting.com)
 Simon Conway / Rob Winder                                   Tel: +44 (0) 20 3727 1000

 

About Advanced Oncotherapy Plc www.avoplc.com (http://www.avoplc.com/)

 

Advanced Oncotherapy, a UK headquartered company with offices in London,
Geneva, The Netherlands and in the USA, is a provider of particle therapy with
protons that harnesses the best in modern technology. Advanced Oncotherapy's
team "ADAM," based in Geneva, focuses on the development of a proprietary
proton accelerator called, Linac Image Guided Hadron Technology (LIGHT).
LIGHT's compact configuration delivers proton beams in a way that facilitates
greater precision and electronic control.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that
will enable them to treat cancer with innovative technology as well as
expected lower treatment-related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging
improvements in delivering proton therapy and actively seeks working
relationships with providers of these innovative technologies. Through these
relationships, the Company will remain the prime provider of an innovative and
cost-effective system for particle therapy with protons.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVREADLNALFAEFA